Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

PresentationAnd with that, thank you so much for joining us here today on a busy day. Brett, I'll turn it over to you.Hello, everyone, and welcome to Oppenheimer's 36th Annual Life Science Conference. I'm Jay Olson, one of the biotech analysts here at Oppenheimer, and it's a pleasure to welcome you to our discussion with Ionis. And it's an honor to introduce Brett Monia, the CEO, and the timing is perfect as the FDA has just accepted the sNDA filing for olezarsen to treat sHTG with a priority review, which ...